Physician profile
Patrick Apilado
NPI 1982114070
$18,776.38
in general payments reported to CMS, 2019-2025
27 companies · $3,191 in 2025
The $3,191 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,816 · 2022: $4,892 · 2023: $3,451 · 2024: $3,426 · 2025: $3,191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,859 · Education: $210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,858.51 |
| Education | $209.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $3,148.51 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $2,934.64 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $2,550.92 | 2021-2025 | |
| Alkermes, INC. | $1,833.52 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Janssen Pharmaceuticals, INC | $1,752.18 | 2021-2025 | Invega Sustenna, Spravato |
| Neurocrine Biosciences, INC. | $1,223.57 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $1,033.69 | 2021-2025 | Uzedy, Austedo Xr, Austedo |
| E.R. Squibb & Sons, L.L.C. | $667.66 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $571.67 | 2021-2025 | Fanapt |
| Axsome Therapeutics, INC. | $466.02 | 2022-2025 | Auvelity |
| Tris Pharma INC | $423.19 | 2021-2024 | Dyanavel Xr, Quillichew Er, Quillivant |
| Sunovion Pharmaceuticals INC. | $358.89 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $298.60 | 2021-2023 | Trintellix |
| Indivior INC. | $279.11 | 2021-2024 | Perseris |
| Supernus Pharmaceuticals, INC. | $275.03 | 2022-2025 | Qelbree, Qelbree |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $216.66 | 2021-2024 | Rexulti |
| Avanir Pharmaceuticals, INC. | $213.75 | 2021-2022 | |
| Almatica Pharma LLC | $136.79 | 2022-2025 | Loreev Xr |
| Eisai INC. | $97.89 | 2021-2022 | |
| Bausch Health US, LLC | $82.36 | 2022-2025 | Aplenzin |
| Sage Therapeutics, LLC | $43.56 | 2025 | Zurzuvae |
| Idorsia Pharmaceuticals US INC | $38.71 | 2022-2023 | Quviviq |
| Merck Sharp & Dohme LLC | $33.70 | 2022 | |
| Corium, LLC | $33.43 | 2024 | Azstarys |
| Janssen Scientific Affairs, LLC | $32.02 | 2025 | Invega Sustenna |
| Neuronetics, INC. | $15.53 | 2023 | Neurostar Tms Therapy System |
| Ironshore Pharmaceuticals INC. | $14.78 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Apilado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.